Amunix Pharmaceuticals, Inc.
United States
41 articles about Amunix Pharmaceuticals, Inc.
-
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
12/21/2021
Sanofi announced that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN® and innovative universal protease-releasable masking technology platform, Pro-XTENTM, to discover and develop transformative T-cell engagers and cytokine therapies for patients with cancer.
-
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
-
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
10/7/2021
Amunix Pharmaceuticals, Inc. (Amunix), today announced that preclinical data from its lead program, AMX-818 (HER2-XPAT), were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics.
-
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
6/23/2021
Amunix Pharmaceuticals, Inc. announced that it has expanded its board of directors with the appointment of Frank Watanabe, CEO of Arcutis and a biopharmaceutical executive with extensive leadership, strategy, operations and financing experience.
-
Several biotech executives provided their thoughts on lessons learned from the pandemic and what they hope or expect to see moving forward in the industry.
-
Amunix Expands its Board of Directors with the Appointment of Industry Veteran, Ciara Kennedy, Ph.D., M.B.A.
5/13/2021
Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engagers and cytokine therapies for patients with cancer, announced the appointment of Ciara Kennedy, Ph.D., M.B.A. to its board of directors.
-
Amunix Presents Preclinical Data at American Academy of Cancer Research (AACR) Annual Meeting from Lead Program AMX-818 Demonstrating Robust Efficacy in HER2 Tumor Models and Enhanced Safety
4/12/2021
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced data were presented from its lead program AMX-818 (HER2-XPAT), at the AACR Annual Meeting.
-
Money on the Move – March 3-9
3/10/2021
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week. -
Amunix Raises $117 Million Series B Financing to Fund its Oncology Pipeline
3/4/2021
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced that it has raised $117 million Series B financing.
-
Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors
1/26/2021
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the appointment of Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
-
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020
12/9/2020
Amunix Pharmaceuticals today shared new data on AMX-818 (HER2-XPAT), the company’s lead clinical candidate T cell engager which targets HER2. Data was presented at the 2020 San Antonio Breast Cancer Symposium.
-
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
9/17/2020
Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors
-
The 2020 virtual meeting of the European Society of Medical Oncology is getting underway and companies are lining up to share information on their latest cancer treatments.
-
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
6/22/2020
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid tumors Prodrug XPATs demonstrated >1000 fold increase in tolerated exposures versus traditional T cell engagers Amunix’s lead program, AMX-818, an XPAT T cell engager targeting HER2+ solid tumors, continues to progress toward the clinic MOUNTAIN VIEW, Calif., June 22, 2020 (GLOBE NEWS
-
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
5/27/2020
Amunix Pharmaceuticals, Inc. announced the appointment of Anne Keane as the Senior Vice President of Regulatory and Quality for Amunix.
-
Nearly two months after inking a licensing deal worth up to $1.5 billion with Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round.
-
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
3/4/2020
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing.
-
Amunix Pharmaceuticals, based in Mountain View, California, entered a licensing deal with Roche. Under the terms of the deal, Roche will pay Amunix $40 million upfront.
-
Amunix Pharmaceuticals Announces Technology Licensing Agreement with Roche to Advance Novel Therapeutics Outside Oncology
1/10/2020
Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing pro-drugs to enable the promise of potent immune-activating biotherapeutics in solid tumors, today announced that it has provided a technology license to F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”) to utilize Amunix’s technology platform, XTEN, to discover and develop non-oncology therapeutics against certain undisclosed targets